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Abstract
Background: Intertumoral heterogeneity represents a significant hurdle to identifying optimized targeted therapies
in gastric cancer (GC). To realize precision medicine for GC patients, an actionable gene alteration-based molecular
classification that directly associates GCs with targeted therapies is needed.
Methods: A total of 207 Japanese patients with GC were included in this study. Formalin-fixed, paraffin-embedded
(FFPE) tumor tissues were obtained from surgical or biopsy specimens and were subjected to DNA extraction. We
generated comprehensive genomic profiling data using a 435-gene panel including 69 actionable genes paired
with US Food and Drug Administration-approved targeted therapies, and the evaluation of Epstein-Barr virus (EBV)
infection and microsatellite instability (MSI) status.
Results: Comprehensive genomic sequencing detected at least one alteration of 435 cancer-related genes in 194
GCs (93.7%) and of 69 actionable genes in 141 GCs (68.1%). We classified the 207 GCs into four The Cancer
Genome Atlas (TCGA) subtypes using the genomic profiling data; EBV (N = 9), MSI (N = 17), chromosomal
instability (N = 119), and genomically stable subtype (N = 62). Actionable gene alterations were not specific
and were widely observed throughout all TCGA subtypes. To discover a novel classification which more
precisely selects candidates for targeted therapies, 207 GCs were classified using hypermutated phenotype
and the mutation profile of 69 actionable genes. We identified a hypermutated group (N = 32), while the
others (N = 175) were sub-divided into six clusters including five with actionable gene alterations: ERBB2 (N = 25), CDKN2A,
and CDKN2B (N = 10), KRAS (N = 10), BRCA2 (N = 9), and ATM cluster (N = 12). The clinical utility of this classification was
demonstrated by a case of unresectable GC with a remarkable response to anti-HER2 therapy in the ERBB2 cluster.
Conclusions: This actionable gene-based classification creates a framework for further studies for realizing precision
medicine in GC.
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Background
Gastric cancer (GC) is the third leading cause of cancer
death worldwide, with the highest incidence in Eastern
Asia [1]. Despite the recent advances in cytotoxic
chemotherapy, unresectable or recurrent GC remains
notorious for the dismal prognosis of patients, with me-
dian survival ranging from 13.0 to 16.6 months [2, 3]. A
number of clinical trials of targeted therapies have been
conducted to improve the outcome of unresectable or
recurrent GC [4]. To date, only two drugs have demon-
strated significant efficacy: trastuzumab, an anti-HER2
antibody [5], and ramucirumab, an anti-VEGF receptor
2 antibody [6, 7]. The other targeted therapies failed to
show any survival benefit in phase III clinical trials,
deemed most likely due to the heterogeneous nature of
GC and the lack of appropriate molecular biomarkers.
Therefore, a better understanding of the molecular pro-
files of GC and optimum patient selection based on the
molecular alterations is necessary to facilitate targeted
therapies for GC.
Large-scale comprehensive molecular profiling using
next-generation sequencing (NGS) technologies has
identified the molecular landscape of a number of can-
cers, including GC [8–13]. The Cancer Genome Atlas
(TCGA) cohort classified heterogeneous GC into four
molecular subtypes: Epstein-Barr virus positive tumors
(EBV), tumors with microsatellite instability (MSI), tu-
mors with chromosomal instability (CIN), and genomi-
cally stable tumors (GS) based on various technologies,
including whole-exome sequencing (WES) [10]. On the
other hand, the Asian Cancer Research Group (ACRG),
using array-based gene expression profiling, identified
four distinct molecular subtypes that were associated
with patient survival and recurrence patterns after sur-
gery: MSI, microsatellite stable (MSS) with epithelial-to-
mesenchymal transition (EMT) signature, MSS with
TP53 activation, and MSS without TP53 activation [12].
These classifications have enabled us to improve our un-
derstanding of the molecular profiles and heterogeneity
of GCs. However, neither of these classifications were
designed to optimize patient selection for targeted ther-
apies. Furthermore, comprehensive analyses such as
WES and array-based profiling, as performed in the
TCGA and ACRG projects, may not be feasible for clin-
ical use due to their higher cost and generation of exces-
sive information about molecular alterations of
unknown biological and clinical significance. For clinical
genetic testing, which is essential for precision medicine
in cancer therapy, panel-based targeted sequencing using
NGS technologies is advantageous because of precise
target enrichment, enhanced depth of coverage, and re-
duced cost [14]. Thus, a clinically useful molecular clas-
sification based on targeted gene panel sequencing
should help to realize precision medicine for GC.
We previously reported the clinical utility of genomic
sequencing with a 415-gene panel in colorectal cancer
[15]. We expanded the target genes to 435, including 69
genes that are associated with the US Food and Drug
Administration (FDA)-approved targeted therapies
(actionable genes), and added the evaluation of EBV
infection and MSI status using NGS technologies. Here,
we generated genomic profiles of 207 Japanese GCs
using the 435-gene panel. Further hierarchical clustering
based on actionable gene alterations successfully classi-




A total of 207 patients histologically diagnosed with GC
between 2009 and 2015 at Niigata University Medical
and Dental Hospital, Niigata Cancer Center Hospital,
Gifu University Hospital, Kyushu University Hospital,
and Keio University Hospital were enrolled. The clinico-
pathological data for the individual patients are summa-
rized in Additional file 1: Table S1. The study included
146 males and 61 females, with a median age of 66 years
(range, 27–87 years). All patients, except for one patient
with liver metastasis, underwent surgical resection with
curative intent. Tumors were histologically staged accord-
ing to the 7th edition of the International Union against
Cancer tumor-node-metastasis (TNM) classification sys-
tem [16]. Collection and use of all specimens in this study
were approved by the Institutional Review Boards of
Niigata University, Niigata Cancer Center Hospital, Gifu
University, Kyushu University, and Keio University.
Informed consent was obtained from all subjects.
Sequencing library preparation
Archival tissue in the form of formalin-fixed, paraffin-
embedded (FFPE) tumor obtained during routine biopsy
(N = 5) and/or surgical resection (N = 202) was used for
analysis. An independent pathologist evaluated tumor
content on hematoxylin and eosin-stained slides for each
study sample to ensure > 20% tumor content was
present. Where applicable, unstained slides were macro-
dissected to enrich for tumor content, and DNA was ex-
tracted using a BioStic FFPE Tissue DNA Isolation Kit
(MO BIO Laboratories, Carlsbad, CA, USA). All sample
preparation, genomic sequencing, and analytics were
performed in a CLIA/CAP-accredited laboratory (KEW,
Cambridge, MA, USA).
Panel-based genomic sequencing
DNA (50–150 ng) fragment libraries were prepared and
enriched for the 435-gene panel with CANCERPLEX
(KEW). CANCERPLEX is a clinically validated 435 gene
panel enriched for coding regions and selected introns
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of genes with known association in cancer (Additional
file 2: Table S2). Sequencing was performed on the
Illumina MiSeq and NextSeq platforms (Illumina, San
Diego, CA, USA) with average 500× sequencing depth.
The CANCERPLEX DNA data sequencing pipeline,
GENEPIPER v5.1, implements a series of public and pro-
prietary algorithms designed to analyze DNA sequencing
information. The analysis starts with demultiplexing by
bcl2fastq v2.17.1.14 from Illumina, in order to obtain
one FASTQ file per input sample. The resulting FASTQ
files are realigned to the human reference sequence
[University of California Santa Cruz (UCSC) hg19/
GRCh37 assembly] using the Burroughs-Wheeler Align-
ment tool (BWA-MEM) in single-end mode [17, 18].
Duplicated reads resulting from PCR over-amplification
or optical duplication are flagged and discarded by the
MarkDuplicates module of Picard tools version 2.5
(http://broadinstitute.github.io/picard/).
Somatic and potential germline single nucleotide vari-
ants (SNVs) and short insertions and deletions (indels)
are called from the cancer tissues using a proprietary
combination of somatic and germline variant callers.
The models used for this purpose take into account
population genetics parameters as well as technical
artifacts observed in the panel of normal samples and
also statistics from databases such as the Genome Ag-
gregation Database (gnomAD), 1000 Genomes, dbSNP,
and COSMIC. All SNV and indel calling, including som-
atic and pathogenic potentially germline variants, was
performed only in genomic regions intended to be cap-
tured by the assay (region of interest (ROI)).
Somatic copy number alterations (SCNAs) are called
by calculating the number of mapped reads and then
performing normalization using the panel of normal
samples (49 samples), GC-content, repeat sequence,
probe density, and other parameters. Copy number
variants are called for exons as well as globally, using a
backbone of probes throughout the genome. We
segment regions using a Fused-Lasso method and
export the results to a VCF file. The threshold for gains
was > 2.5-fold and for loss < 0.75-fold. Fused genes
(structural variants (SVs)) were detected only if at least
one end mapped to any of the following genes: AKT3,
ALK, BRAF, EGFR, ETV1, ETV4, ETV5, ETV6, FGFR2,
FGFR3, MET, NOTCH1, NOTCH2, NRG1, PDGFRA,
RAF1, RET, ROS1, TMPRSS2. Variants were filtered or
flagged according to technical quality (e.g., coverage,
allelic fraction, number of supporting reads), presence
in previously characterized normal samples, or pres-
ence/absence in the following databases: dbSNP, ExAC,
COSMIC, ClinVar, KEW. SNVs and indels in VCF format
were annotated using ClinEff 1.0e and hg19 database
(UCSC reference with RefSeq identifiers) and the output
was adapted according to HGVS recommendations.
The tumor mutation burden (TMB), defined as the
rate of peptide-changing SNVs per megabase, was deter-
mined for all tumors. To estimate the TMB, after stand-
ard filtering had been applied, only SNVs with a
mutation allelic fraction of at least 10% and with high or
moderate putative impact were retained. Tumors were
tested for the presence of microsatellite instability (MSI)
based on an extended loci panel. In addition to the Be-
thesda panel, a collection of 950 regions consisting of
tandem repeats of one, two, or three nucleotides of
minimum length of 10 bases. The number of indels
within the ROI was calculated and tumors were classi-
fied as MSI-high (MSI-H) or microsatellite stable (MSS).
Tumors were also analyzed for the presence of HPV-16,
HPV-18, and EBV (HHV-4) viral sequences. The reference
genomes used were GI:310698439, GI:9626069, and
NC_007605 for HPV-16, HPV-18, and EBV, respectively.
The percentage of total number of reads mapped to the
viral genomes was calculated and samples were designated
as positive based on empirical cutoffs of 0.02, 0.01, and
0.0005% of reads that were mapped to HPV-16, HPV-18,
and EBV genomes, respectively.
The specificity and sensitivity of all variant and bio-
marker detection was validated as previously described
[19]. All non-synonymous genomic changes with low
population frequency and allele fraction above 10%
underwent a semi-automated curation and annotation
process in GENEKEEPER, a proprietary curation tool
and database used to determine pathogenicity and clin-
ical relevance of alterations. We use the catalogue of
FDA-approved drugs, the NCCN treatment guidelines,
multiple mutation databases, and current scientific lit-
erature to determine if the variant protein is a target of a
FDA-approved drug, a target of a drug in clinical devel-
opment, or confers resistance to known treatments.
Clinical trials are identified using ClinicalTrial.gov and
other tools (e.g., Thompson Reuter Cortellis and Pharma
Intelligence Trialtrove). Each variant is classified accord-
ing the Association of Molecular Pathology (AMP)
guidelines for somatic cancer variants [19]. Any variants
classified as benign or likely benign were excluded from
this study. To align mutations with their protein do-
mains, genomic data were analyzed in Mutation Mapper
(http://www.cbioportal.org/) for ERBB2 in Japanese GC.
Genomic profiles of 435 genes in TCGA GCs
Genomic data and clinicopathological characteristics
from a total of 295 tumor samples of GC published in
the TCGA database were downloaded from cBioPortal
(http://www.cbioportal.org/) for inclusion in this study.
To compare the clinicopathological characteristics
between Japanese and TCGA GC, two-tailed Fisher’s
exact test and Mann–Whitney U-test were applied for
categorical and continuous variables, respectively. We
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down-sampled whole exome sequencing data to the 435
genes within the CANCERPLEX panel, including muta-
tions (N = 289) and putative copy-number alterations
from GISTIC (N = 293) for tumors that had sequencing
data. The Oncoprint analysis tool (http://www.cbiopor
tal.org/) was used to plot mutational data among differ-
ent tumors. We evaluated mutation burden using the
mutation data limited to 435 panel genes from TCGA
GC samples (N = 289). STAD mutation data for the
TCGA GCs were downloaded from the Broad GDAC
Firehose website (https://gdac.broadinstitute.org/). Simi-
lar to the 435-gene panel bioinformatics pipeline, silent
mutations that were not protein-altering were removed
from the dataset. To compare mutation burden of the
435 gene panel to TCGA WES data on the same
samples, the dataset of SNPs was down-sampled to the
435 genes in the panel, and the mutation rate deter-
mined in the panel was calculated as mutations/Mb.
Correlations between the mutation rate of the 435 genes
and of TCGA WES data were evaluated using the
Spearman correlation coefficient.
Gene clustering analysis
Mutation data from non-hypermutated Japanese GCs
(N = 175) were extracted and clustered by mutated gene
patterns using a method described previously [15]. Two
different sets of genes—all 435 panel genes and 69
actionable genes—were used for clustering. The number
of mutated genes in common related to donors i and j is
presented as an element cij of an N × N matrix, where N
is the number of non-hypermutated donors. In order to
normalize the elements of this N dimension symmetric
matrix into values ranging from 0 to 1, the original
element was replaced by 1/(cij + 1), which indicates the
level of similarity between donors i and j. Because of this
normalization, donors with more mutated-genes in
common would more likely come from a relatively close
group. Consequently, a matrix with the normalized
values between all donors was created. Hierarchical
clustering of the matrix was performed for classifying
donor groups with different mutated gene patterns by
Euclidean distance and Ward’s clustering. This clustering
was performed using R (https://www.r-project.org/).
Clustering stability was evaluated by R package clValid
for statistical and biological validation of clustering re-
sults, and the most stable clusters were determined [20].
Statistical analysis of clinicopathological characteristics
To estimate associations between co-mutated gene pat-
terns and clinicopathological characteristics, two-tailed
Fisher’s exact test was applied to categorical variables
by comparing the distribution in a cluster group to that
of all the donors in the other groups. Mann–Whitney
U-test was used for continuous variables. Note that in
the case of statistical signature for hypermutated do-
nors, two-tailed Fisher’s exact test was conducted
against non-hypermutated donors as a reference set. All
statistical tests were performed using the R package
statmod (https://cran.r-project.org/web/packages/stat-
mod/index.html), and differences with P < 0.05 are
regarded as statistically significant.
Results
Overall genomic alterations detected using the 435-gene
panel in Japanese GCs
Comprehensive genomic sequencing using the 435-gene
panel detected at least one alteration of a cancer-related
gene in 194 out of 207 patients (93.7%). Regarding 69
actionable genes which associated with FDA-approved
targeted therapies, at least one alteration was detected in
141 patients (68.1%). Among 435 genes, mutations
(single nucleotide substitutions (SNPs) and/or indels),
somatic copy number alterations (SCNAs), and both
alterations were found in 173, 31, and 30 genes, respect-
ively. In 207 Japanese GC patients, the most frequently
mutated gene was TP53 (53.1%), followed by ARID1A
(15.9%) and CDH1 (14.0%). ERBB2 amplification (12.1%)
was the most frequently observed SCNA, followed by
CCNE1 (7.2%) and KRAS (5.8%) amplification (Table 1).
Molecular classification according to TCGA subtype in
Japanese GCs
The 207 Japanese GCs were classified into four TCGA
subtypes based on the genomic profiling data from the
435-gene panel (Fig. 1a). Nine tumors (4%) positive for
EBV-DNA sequence were classified as EBV subtype.
MSI-high (MSI-H) status was found in 17 tumors (8%),
and they were classified as MSI subtype. Finally, the
remaining 181 tumors were divided into CIN and GS
subtypes using SCNA status. In the previous TCGA
study, TP53 mutations were frequently observed in the
CIN subtype, and tumors with a diffuse type of Lauren
classification were enriched in the GS subtype. To
match this classification scheme, we defined SCNA-
high tumors as those with four or more SCNA loci
(Additional file 3: Figure S1). As a result, 119 SCNA-
high tumors (58%) were categorized as CIN subtype,
and the remaining 62 tumors (30%) with SCNA-low as
GS subtype (Fig. 1b). We compared the distribution of
the four subtypes between Japanese and TCGA GCs.
Regarding regional differences between enrolled
patients, the nationality of 75% of patients in the
TCGA study is European or American (Additional file
3: Figure S2a); on the other hand, all patients included
in our study were Japanese. However, the clinicopatho-
logical characteristics of each subtype of Japanese GC
were roughly comparable to those of the TCGA GCs
(Additional file 3: Figure S2b–f ). The proportion of the
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MSI subtype was lower, and that of the GS subtype was
higher, in Japanese GCs than in TCGA GCs (P < 0.01;
Fig. 1c). Because genomic profiling of actionable genes
may lead to strategies for optimal targeted therapies in
GC, we examined actionable gene alterations that were
observed at a frequency of 5% or more in Japanese
GCs. Interestingly, these alterations were not specific to
a TCGA subtype (Fig. 1d).
Hypermutated tumors in Japanese GCs
Recently, hypermutated tumors have been considered
to have a higher response to immunotherapy because
of the development of neo-antigens [21, 22]. In the pre-
vious TCGA study of GC, hypermutated tumors were
defined as MSI-H tumors [10]. The mutation rate of
MSI-H tumors (31.5 counts/Mb, range 18.5–66.9) was
significantly higher than that of MSS tumors (11.2
counts/Mb, range 3.1–27.7) in Japanese GCs (P < 0.01).
We defined hypermutated tumors as those with a mu-
tation rate of more than 18.5 counts/Mb, which was
the lowest value in MSI-H tumors (Fig. 2). To validate
the cutoff value of mutation rate, WES data of TCGA
GCs was down-sampled to the 435 genes, and mutation
rate calculated. A high correlation of mutation rate
between WES and the 435-gene panel was demon-
strated (correlation coefficient of 0.966). The lowest
mutation rate of MSI-H tumors in TCGA GCs was
16.4 counts/Mb, and was nearly equivalent to that in
Japanese GCs. As a result, we identified 32 tumors
(15.5%) as hypermutated tumors, which not only in-
cluded the MSI subtype but also some tumors from the
EBV, CIN, and GS subtypes (Fig. 1a).
Clustering based on gene alterations for targeted therapy
in Japanese GCs
Actionable gene alterations and hypermutated pheno-
types were widely observed throughout all TCGA sub-
types in our analysis (Fig. 1a, d). Novel classifications,
directly associated with these alterations, may better pin-
point candidates for targeted therapies than TCGA sub-
types. Thus, our 207 tumors were classified using the
hypermutated phenotype and alteration profile of the 69
actionable genes. Hypermutated tumors (N = 32) were
identified, and the remaining non-hypermutated tumors
(N = 175) were subdivided into six clusters by hierarch-
ical clustering (Fig. 3). Firstly, tumors with ERBB2 alter-
ations were classified as cluster 1 (N = 25). Remaining
tumors without ERBB2 alterations were classified into
two large clusters according to the enrichment of action-
able gene alterations. The cluster with enrichment of the
major alterations were subsequently divided into four
clusters (clusters 2–5) based on intrinsic gene alterations
in CDKN2A/B (N = 10), KRAS (N = 10), BRCA2 (N = 9),
or ATM (N = 12). Cluster 6 (N = 109) included tumors
with minor alterations and those with no alterations in
actionable genes. Using this clustering scheme, FDA-
approved targeted therapies could be associated with a
majority of tumors, including hypermutated tumors,
those in clusters 1–5 and a part of cluster 6.
In addition, we performed hierarchical clustering based
on the 435-gene alterations to assess the associations
between overall genomic profile and clinicopathological
features. Non-hypermutated tumors were classified into
nine clusters (Additional file 3: Figure S3a). We identified
the clusters which have specific clinicopathological
features (Additional file 3: Figure S3b). Tumors in cluster
9 (N = 16), which are characterized by concomitant alter-
ations of TP53 and ERBB2, significantly associated with
high counts of SCNA (P < 0.01) and the intestinal type of
Lauren classification (P < 0.05) compared with tumors in
all other clusters. On the other hand, tumors in cluster 4
with primary mutated gene CDH1 significantly associated
with young age (P < 0.05), low counts of SCNA (P < 0.01),
female gender (P < 0.01), and diffuse type of Lauren classi-
fication (P < 0.01). These findings suggest that genomic
profiling generated by the 435-gene panel reflects the clin-
icopathological features in Japanese GCs.






1 TP53 53.1% ERBB2 AMP 12.1%
2 ARID1A 15.9% CCNE1 AMP 6.8%
3 CDH1 14.0% KRAS AMP 5.8%
4 BRCA2 10.6% ZNF217 AMP 5.8%
5 ARID1B 10.1% CDKN2A DEL 5.3%
6 ATM 9.7% CDKN2B DEL 5.3%
7 PIK3CA 8.7% GATA4 AMP 4.3%
8 APC 8.2% MYC AMP 2.4%
9 ACVR2A 7.2% CCND3 AMP 1.9%
10 CHD2 6.3% CD274 AMP 1.9%
11 KMT2D 6.3% CDK6 AMP 1.9%
12 RNF43 5.8% EGFR AMP 1.9%
13 EPHA2 5.8% FGFR2 AMP 1.9%
14 TGFBR2 5.3% JAK2 AMP 1.9%
15 FLCN 4.3% GNAS AMP 1.9%
16 PALB2 4.3% CCND1 AMP 1.4%
17 PTPRT 4.3% MET AMP 1.4%
18 RAD50 4.3% HSP90AB1 AMP 1.4%
19 BRCA1 3.9% SMAD4 DEL 1.4%
20 STK11 3.9% TEK DEL 1.4%
AMP amplification, DEL deletion, SCNA somatic copy number alteration
Bold gene symbols indicate genes from the 69 actionable genes for
FDA-approved targeted therapies
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Details of gene alterations and a remarkable case in the
ERBB2 cluster (cluster 1)
Anti-HER2 therapy with trastuzumab is recommended
as a first line therapy for HER2-overexpressing GC [5].
Tumors harboring ERBB2 alterations were primarily
assigned into cluster 1 in our study. ERBB2 amplifica-
tion, mutation, and both alterations were detected in
22, two, and one tumor, respectively. Details of ERBB2
mutations in the Japanese GCs are shown in Fig. 4a. All
the mutations detected in cluster 1 were S310F, which
is well-known to activate HER2 signaling [23, 24].
Tumors with the S310F mutation have been reported
to have good response to anti-HER2 therapy [25].
Within cluster 1, one patient demonstrated a remark-
able response to anti-HER2 therapy (Fig. 4b–d). In brief,
this patient was a 55-year old woman with unresectable
GC because of extensive abdominal and paraaortic
lymph node metastases. HER2 overexpression was con-
firmed by immunohistochemistry in the biopsy speci-
men, and trastuzumab combined with chemotherapy
was administered. After seven courses of treatment,
complete response according to RECIST ver. 1.1 was
observed in abdominal and paraaortic lymph node
metastases. The primary tumor of the stomach also
decreased in size, although histological examination of
the endoscopic biopsy specimen revealed residual
tumor. A PET-CT scan showed abnormal uptake only
in the primary tumor of the stomach. Therefore, we
performed distal gastrectomy with regional and
paraaortic lymphadenectomy, and achieved curative
Fig. 1 The Cancer Genome Atlas molecular subtypes in 207 Japanese gastric cancers (GCs). a The 207 Japanese GCs are classified into four
molecular subtypes; Epstein-Barr virus-positive (EBV, red), tumor with microsatellite instability (MSI, blue), tumors with chromosomal instability
(CIN, purple), and genomically stable tumors (GS, green). Color tiles indicate pathological and molecular characteristics of of GC. Tumors are
ordered by mutation rate and the red dots indicate hypermutated tumors with a mutation rate of more than 18.5 counts/Mb, which was the
lowest value in the MSI subtype. b Classification of 207 Japanese GCs into TCGA molecular subtypes. The cutoff value of somatic copy number
alterations (SCNAs) is defined as four loci according to the status of TP53 mutation and histological type (Additional file 3: Figure S1).
c Distribution of molecular subtypes in 207 Japanese (upper) and TCGA (lower) GCs. d Landscape of frequently observed actionable gene
alterations (5% or more) in 207 Japanese GCs classified by TCGA subtype. Alteration color indicates the class of gene alterations
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resection. Histological examination revealed no viable
tumor cells in the abdominal and paraaortic lymph
nodes. Genomic alterations in the biopsy specimen
obtained before treatment were retrospectively exam-
ined using the 435-gene panel. Consistent with the
immunohistochemistry, ERBB2 amplification was de-
tected. Other alterations detected were ZNF217 ampli-
fication and TP53 mutation. Concomitant alterations in
the ERBB2 downstream pathway, which confer resist-
ance to trastuzumab therapy, were not observed in the
tumor of this patient.
Discussion
GC is a highly heterogeneous disease with various histo-
logical phenotypes and molecular diversity. Intertumoral
heterogeneity represents a significant hurdle to identify-
ing optimized targeted therapies in GC. Stratification of
patients based upon the distinctive genomic alterations
in their tumors is needed to realize precision medicine
in GC. To the best of our knowledge, the current study
is the first to demonstrate the actionable gene-based
molecular classification associated with FDA-approved
targeted therapies using panel-based targeted sequen-
cing. We generated comprehensive genomic profiling
data for 207 Japanese GCs using a 435-gene panel in-
cluding the evaluation of EBV infection and MSI status
based on NGS technologies. We identified five clusters
by hierarchical clustering according to alterations in 69
actionable genes in addition to hypermutated status,
which are associated with FDA-approved targeted ther-
apies. Our study highlighted the potential of panel-based
targeted sequencing to provide reliable information for
realizing precision medicine in GC.
Large-scale genome projects have attempted to iden-
tify distinct molecular subtypes to help define the het-
erogeneity of GCs; however, a clinically useful
classification that is relevant to targeted therapies is yet
to be found for GC. TCGA molecular subtypes are a
reasonable classification which reflects the tumor biol-
ogy and associates with clinicopathologic features of GC
[10]. ACRG molecular subtypes, established using gene
expression and genome-wide copy number microarray
data, were associated with survival outcome and recur-
rence patterns in patients with GC after surgery [12].
However, it remains unclear whether these molecular
subtypes can provide optimum targeted therapies in GC.
In this study, 207 Japanese GCs were classified into
TCGA molecular subtypes, and we showed that alter-
ations in actionable genes are not specific to TCGA mo-
lecular subtype, but rather are widely distributed
throughout the subtypes. Therefore, TCGA molecular
subtype may not be directly useful for clinical applica-
tions to optimize targeted therapies. Novel classifications
Fig. 2 Mutation rates in Japanese and The Cancer Genome Atlas gastric cancers. a Mutation rate from Japanese GCs was determined by the number
of non-synonymous SNVs in the 435-gene panel. Red, MSI-H; gray, MSS; HM, hypermutation. b WES data from TCGA GCs was down-sampled to the
content of the 435-gene panel. Red, MSI-H; gray, MSS; HM, hypermutation. c Correlation between mutation rates determined using the 435-gene panel
and WES data of TCGA GCs
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which more precisely select candidates for targeted ther-
apies are necessary to realize precision medicine in GC.
We successfully classified 207 tumors into clusters dir-
ectly associated with FDA-approved targeted therapies
according to the alterations of 69 actionable genes and
hypermutated phenotype. We identified the clusters with
enrichment of CDKN2A/B, KRAS, ATM, or BRCA2 al-
terations, in addition to ERBB2 ones. ATM and BRCA1/
2 play an essential role in double-strand DNA break re-
pair pathway, and the deficiency of this pathway caused
by the alterations of these genes were associated with
high sensitivity to the PARP inhibitors in solid tumors,
including GC [26, 27]. A phase II clinical trial revealed
the efficacy of olaparib as a second line therapy in recur-
rent or metastatic GC with negative expression of ATM
protein by immunohistochemistry [28]. However, phase
III clinical trial did not show the significant overall
survival benefit of olaparib in this population
(NCT01924533) [29]. Further clinical studies of PARP
inhibitors for BRCA1/2 or ATM mutated GCs are neces-
sary to establish the appropriate biomarker and to reveal
the benefit of this therapy. KRAS mutation and amplifi-
cation lead to an activation of the RAF-MEK-ERK path-
way, which is critical to pathogenesis and progression in
many cancers [30]. KRAS itself is difficult to directly in-
hibit; therefore, inhibition of the downstream RAF-
MEK-ERK pathway is considered a promising treatment
for KRAS-mutated tumors [31]. A clinical benefit of the
FDA-approved MEK inhibitor trametinib has been par-
tially demonstrated in cancers with a KRAS mutation
[32, 33]. CDKN2A/B protein products restrict cell-cycle
progression by inhibiting CDK4/6 kinase activity, and
aberrations in these genes lead to cancer progression by
dysregulation of the cell cycle [34]. The association be-
tween CDKN2A/B deletion and the sensitivity to palbo-
ciclib, an FDA-approved CDK4/6 inhibitor, has been
demonstrated in many cancers [35–38]. Therefore, it is
worth investigating the clinical utility of the above-
mentioned targeted therapies for GCs with corresponding
gene alterations to establish precision medicine in GC.
Our hierarchical clustering based on actionable gene
alterations identified the cluster with ERBB2 alterations
as one of the major clusters. Patients with tumors har-
boring ERBB2 amplification (N = 22) are candidates for
trastuzumab, an anti-HER2 monoclonal antibody, as a
standard first line therapy for unresectable metastatic
GC. Excitingly, a remarkable response to trastuzumab
therapy was observed in one of the ERBB2-amplified
Fig. 3 Clustering based on 69 actionable gene alterations. According to co-alteration patterns of the 69 actionable gene subset, 175 non-hypermutated
tumors are divided into six clusters, and the gene alteration spectrum and TCGA molecular subtype of each tumor is demonstrated as color tiles.
Alteration in color indicates the class of gene alteration. The 32 hypermutated tumors are shown on the right (brown). The specific gene alteration and
proposal for targeted therapy are presented under each cluster. Fourteen genes which have no alterations in 207 tumors are not included in this figure
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tumors categorized into this cluster, and genomic se-
quencing identified no concomitant alterations in the
ERBB2 downstream pathway. Alterations in the PI3K/
mTOR and MAPK pathways and amplification of other
receptor tyrosine kinases are proposed mechanisms of
trastuzumab resistance [39–41]. Genomic profiling using
the 435-gene panel enabled us to simultaneously exam-
ine the gene alterations of these pathways in single test-
ing, and has the potential to provide reliable information
to predict treatment response and to overcome resist-
ance for targeted therapies [42, 43].
Recent advances on the genetics of GC are pointing
toward an enrichment of the mutations involved in
double-strand DNA break repair via homologous recom-
bination (HR). Alexandrov et al. [44] demonstrated that
7–12% of GCs have deficiencies in this pathway using a
large-scale mutational signatures analysis. Sahasrabudhe
et al. [45] identified 11 of 362 GC cases with germline
mutations in PALB2, BRCA1, or RAD51C, which regu-
late HR. In this study, we identified the high frequency
of mutations in HR genes, including BRCA1/2, ATM,
PALB2, and RAD50 (Table 1). This results indicates that
defective HR is a crucial genetic aberration in Japanese
GCs, similar to recent studies. Ovarian and breast can-
cers with defective HR have high sensitivity to platinum
agents as well as PARP inhibitors [46, 47]. Platinum-
based chemotherapy is a mainstay of current treatment
for advanced GC [2, 4]. Therefore, the assessment of de-
fective HR using panel-based targeted sequencing might
allow optimization of patient selection for platinum-
based chemotherapy in GC.
Previous comprehensive studies characterized diffuse
type GCs as tumors with a low frequency of mutation
and SCNA, which were classified as GS subtype in the
TCGA study [10] or MSS/EMT subtype in the ACRG
study [12]. Promising therapeutic targets are hard to
identify in these subtypes because of the genomic stabil-
ity. Indeed, in our hierarchical clustering analysis, diffuse
type and GS tumors were significantly enriched in 63
tumors with no actionable alterations which associated
with FDA-approved targeted therapies: 52.4 and 46.0%,
respectively (Additional file 3: Figure S4). Several studies
Fig. 4 Details of ERBB2 alterations and a case of remarkable response to anti-HER2 therapy in the ERBB2 cluster. a Mutations of ERBB2
identified in 207 Japanese GCs are aligned to the protein domain. Patient samples are further plotted by mutation status. b Abdominal
enhanced CT before trastuzumab therapy (upper panel) demonstrated extensive metastases in abdominal (arrow head) and paraaortic
(arrow) lymph nodes. All the metastatic lymph nodes were remarkably reduced in size after trastuzumab therapy (lower panel). c Abdominal
lymph nodes were reduced in size, and paraaortic lymphadenectomy was performed (upper panel). Histological examination revealed no
viable tumor cells in the abdominal and paraaortic lymph nodes (lower panel, hematoxylin and eosin, original magnification × 40).
d Genomic sequencing in biopsy specimen obtained before treatment (left panel, hematoxylin and eosin; right panel, anti-HER2 antibody)
identified ERBB2 and ZNF217 amplification and TP53 mutation. However, concomitant alterations in the ERBB2 downstream pathway were
not observed in the tumor of this patient
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using WES or WGS focusing on diffuse type GCs were
conducted to understand the molecular background and
to explore therapeutic targets [9, 48]. However, promis-
ing targeted therapies are not currently developed in dif-
fuse type GCs. Further challenges exist in developing
effective targeted therapies for these tumors with
genomic stability.
Except for trastuzumab, targeted therapies proposed
by our actionable gene-based classification are not cur-
rently approved for GC. Future studies are needed to
determine the effectiveness of actionable gene-based
classifications to improve patient outcomes. Clinical tri-
als for targeted therapies, coupled with genomic profil-
ing for optimum patient selection, are required to
demonstrate clinical utility, including treatment outcome
and cost-effectiveness. Nonetheless, we believe that our
genomic profiling data and classification are informative
for future studies to explore the rationale for precision
medicine in GC because our study represents the most
extensive large-scale targeted sequencing project in
Japan where a high incidence of GC is observed.
Conclusions
We generated genomic profiling data for 207 Japanese
GCs using the 435-gene panel with NGS technology.
Our actionable gene-based classification creates a frame-
work for further studies aimed at realizing precision
medicine in GC.
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